



**GENETICS AND GENOMICS IN  
CLINICAL RESEARCH COURSE**

**Copy Number Variations (CNVs)**

**October 1<sup>st</sup> 2013**


Fady M. Mikhail, MD, PhD

Associate Professor

Department of Genetics

# Copy number variations (CNVs)


- Stretches of genomic DNA present in more than or less than two copies that can range in size from kilobases (kb) to megabases (Mb)
- Cannot be identified by G-banded chromosome analysis, but can be identified by cytogenomic array methodologies and whole genome sequencing
- Can be germline or somatic
- Can be inherited or sporadic (*de novo*). Large *de novo* CNVs are more likely to be disease causative



# Copy number variations (CNVs) (cont'd)

- Recent studies have indicated that CNVs are widespread in the human genome and are a significant source of human genetic variation accounting for population diversity and human disease. Between any two individuals the number of base-pair differences due to CNVs is >100-fold higher compared with SNPs
- The phenotypic effects of CNVs are sometimes unclear and depend on whether they span dosage-sensitive genes or regulatory sequences
- In a clinical setting, CNVs have been categorized into five groups (according ACMG practice guidelines):
  1. Benign
  2. Variant of unknown significance (VOUS) - most likely benign
  3. VOUS - uncertain significance
  4. VOUS - most likely pathogenic
  5. Pathogenic

# Size and frequency of major categories of genetic variants




# Genomic rearrangements versus base pair alterations

|  | <b>Genomic rearrangements<br/>(including CNVs)</b>  | <b>Base pair (bp) alterations</b>  |
|--|---|--|
| <b>Size</b>  | Thousands to millions of bp   | Small scale gene mutations<br>(e.g. point mutations)   |
| <b>Gene content</b>                                    | One to several genes  | One gene   |
| <b>Molecular mechanism</b>                             | <ul style="list-style-type: none"> <li>Mechanisms mediated or stimulated by genomic architecture</li> <li><u>OR</u></li> <li>Exogenous factors (e.g. ionizing radiation)</li> </ul> | <ul style="list-style-type: none"> <li>Errors of DNA replication and/or repair</li> <li><u>OR</u></li> <li>Exogenous factors (e.g. chemical mutagens)</li> </ul> |
| <b>Locus-specific mutation rate (<math>\mu</math>)</b> | <u>CNVs</u> : $1.7 \times 10^{-6}$ - $1.2 \times 10^{-4}$   | <u>Single-nucleotide changes</u> : $1.8$ - $2.5 \times 10^{-8}$  |
| <b>Method of detection</b>                             | <ul style="list-style-type: none"> <li>G-banded chromosomes</li> <li>FISH</li> <li>Cytogenomic arrays</li> </ul>  | <ul style="list-style-type: none"> <li>DNA sequencing</li> <li>Other molecular techniques</li> </ul>   |

# Benign CNVs


- A recent estimate of the proportion of the human genome that is structurally variant (i.e. benign CNVs) is in the order of ~5-10%
- The majority (>95%) of benign CNVs in humans are <100 kb in size



# Can CNVs cause disease?

- Most CNVs are benign variants that will not directly cause disease
- CNVs that affect critical developmental genes can cause disease
- Recent reviews have listed 17 conditions of the nervous system alone – including Parkinson's Disease and Alzheimer's Disease – that can result from copy number variation
- Genes that are involved in the immune system and in brain development and activity – two functions that have evolved rapidly in humans – tend to be enriched in CNVs

# Molecular mechanisms by which genomic rearrangements can convey phenotypes



# Interpretation of the clinical significance of CNVs

**Table 1. Assessment of Pathogenicity of a CNV<sup>a</sup>**


| Primary Criteria  | Indicates CNV Is Probably |        |
|---|---------------------------|--------|
|   | Pathogenic                | Benign |
| 1. a. Identical CNV inherited from a healthy parent <sup>b</sup>  |                           | ✓      |
| b. Expanded or altered CNV inherited from a parent  | ✓                         |        |
| c. Identical CNV inherited from an affected parent  | ✓                         |        |
| 2. a. Similar to a CNV in a healthy relative  |                           | ✓      |
| b. Similar to a CNV in an affected relative   | ✓                         |        |
| 3. CNV is completely contained within genomic imbalance defined by a high-resolution technology in a CNV database of healthy individuals                    |                           | ✓      |
| 4. CNV overlaps a genomic imbalance defined by a high-resolution technology in a CNV database for patients with ID/DD, ASD, or MCA                          | ✓                         |        |
| 5. CNV overlaps genomic coordinates for a known genomic-imbalance syndrome (i.e., previously published or well-recognized deletion or duplication syndrome) | ✓                         |        |
| 6. CNV contains morbid OMIM genes <sup>c</sup>  | ✓                         |        |
| 7. a. CNV is gene rich  | ✓                         |        |
| b. CNV is gene poor   |                           | ✓      |

**Table 1. Assessment of Pathogenicity of a CNV<sup>a</sup>**


|  | Indicates CNV Is Probably |        |
|--|---------------------------|--------|
|  | Pathogenic                | Benign |
| <b>General Findings<sup>d</sup></b>                          |                           |        |
| 1. a. CNV is a deletion                                      | ✓                         |        |
| b. CNV is a homozygous deletion                              | ✓                         |        |
| 2. a. CNV is a duplication (no known dosage-sensitive genes) |                           | ✓      |
| b. CNV is an amplification (greater than 1 copy gain)        | ✓                         |        |
| 3. CNV is devoid of known regulatory elements                |                           | ✓      |

Miller DT et al. Am J Hum Genet 2010;86:749-64

# CNV burden across various neurodevelopmental phenotypes




## Variable expressivity of hotspot CNVs



The frequency of CNV deletions and reciprocal duplications for six genomic hotspots associated with neurological disease are shown (ID/DD, autism, epilepsy, schizophrenia, and bipolar disorders).









# Array Comparative Genomic Hybridization (array CGH)




# Cytogenomic array methodologies

| <b>Array CGH</b>  | <b>SNP arrays</b>   |
|---|---|
| Single-sequence oligonucleotides of ~60 bp                | Two 20–60 bp oligonucleotides of different sequence                   |
| Two labeled DNAs (patient and control) per hybridization  | Only patient DNA labeled and hybridized                               |
| Resolution down to size of oligonucleotides; exon by exon | Resolution limited by SNP distribution                                |
| No detection of UPD or consanguinity                      | Able to detect consanguinity and most UPD                             |
| Limited SNP addition possible recently                    | Detection of most known clinically relevant CNVs but not exon by exon |

# Agilent 8x60k array






# Agilent 8x60k array – subarray 2\_1







# 16p11.2 microdeletion





# CNV Databases

- Database of Genomic Variants: <http://projects.tcag.ca>
- UCSC Genome Browser: <http://www.genome.ucsc.edu/cgi-bin/hgGateway>
- Ensembl Database: [http://useast.ensembl.org/Homo\\_sapiens/Info/Index](http://useast.ensembl.org/Homo_sapiens/Info/Index)
- NCBI Map Viewer: <http://www.ncbi.nlm.nih.gov/projects/mapview/>
- DECIPHER Database: <http://decipher.sanger.ac.uk/>
- ISCA Consortium: <https://www.iscaconsortium.org/>

# Conclusions

- CNVs are widespread in the human genome and are a significant source of human genetic variation accounting for population diversity and human disease
- High-resolution cytogenomic array is a powerful and efficient method (in both clinical and research settings) for detecting pathogenic CNVs in patients with DD, ID, ASD, and MCAs
- Clinical high-resolution cytogenomic array has proven to have an ~15-20% overall detection rate of genomic rearrangements in these patients
- A specific genetic diagnosis in these cases facilitates comprehensive medical care and accurate recurrence risk counseling for the family